ADC Therapeutics SA (ADCT)Healthcare | Biotechnology | Epalinges, Switzerland | NYSE
4.28 USD
-0.10
(-2.283%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 4.25 -0.03 (-0.030%) ⇩ (April 17, 2026, 6:17 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:12 a.m. EDT
Despite fundamental distress with negative EBITDA and low cash balances, ADCT presents a high-conviction short-term momentum play priced to move. The massive analyst 'Strong Buy' consensus (Mean 1.17) and the overwhelming options flow favoring calls over puts suggest the market is betting on a VLSM (Village at Stonegate) or royalty financing catalyst reversal. However, book value is negative and cash is being deployed rapidly; this is a trade on momentum and binary event upside, not a fundamental value accrual. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.096324 |
| MSTL | 0.099541 |
| AutoETS | 0.118363 |
| AutoARIMA | 0.118364 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.564 |
| Excess Kurtosis | 0.13 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.64 |
| Market Cap | 543,749,824 |
| Forward P/E | -2.87 |
| Beta | 1.95 |
| Profit Margins | -175.31% |
| Website | https://www.adctherapeutics.com |
As of April 19, 2026, 12:12 a.m. EDT: Options sentiment is distinctly bullish with heavy call open interest concentrated at strikes 5.0 and 7.5. Call volume significantly outweighs put volume across all expirations (otm_oi_pct of 0.17 for puts vs implied level for calls). The ATM Anchor for calls (Strike 5.0) shows strong positioning compared to the ATM Anchor for puts (Strike 2.5), which has minimal recent flow (Vol 10 > OI 1 only in Oct puts). Implied volatility is skewed heavily toward downside protection in the near term (IV 15.88% for 4/17 puts) but this contrasts with the directional volume bias toward upside. Speculators are positioning for a move higher toward the 5.0-7.5 strike region.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.4796748 |
| Address1 | BiopOle |
| Address2 | Route de la Corniche 3B |
| All Time High | 56.59 |
| All Time Low | 0.36 |
| Ask | 4.7 |
| Ask Size | 200 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 981,000 |
| Average Daily Volume3 Month | 867,072 |
| Average Volume | 867,072 |
| Average Volume10Days | 981,000 |
| Beta | 1.952 |
| Bid | 4.25 |
| Bid Size | 300 |
| Board Risk | 8 |
| Book Value | -1.478 |
| City | Epalinges |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.28 |
| Current Ratio | 4.366 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 4.5 |
| Day Low | 4.28 |
| Earnings Call Timestamp End | 1,773,145,800 |
| Earnings Call Timestamp Start | 1,773,145,800 |
| Earnings Timestamp | 1,773,145,800 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | -105,390,000 |
| Ebitda Margins | -1.2953999 |
| Enterprise To Ebitda | -6.85 |
| Enterprise To Revenue | 8.874 |
| Enterprise Value | 721,960,832 |
| Eps Forward | -1.49 |
| Eps Trailing Twelve Months | -1.12 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.0596 |
| Fifty Day Average Change | 0.22040033 |
| Fifty Day Average Change Percent | 0.054291148 |
| Fifty Two Week Change Percent | 247.96748 |
| Fifty Two Week High | 4.98 |
| Fifty Two Week High Change | -0.6999998 |
| Fifty Two Week High Change Percent | -0.1405622 |
| Fifty Two Week Low | 1.2 |
| Fifty Two Week Low Change | 3.0800002 |
| Fifty Two Week Low Change Percent | 2.5666666 |
| Fifty Two Week Range | 1.2 - 4.98 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,589,808,600,000 |
| Float Shares | 100,859,244 |
| Forward Eps | -1.49 |
| Forward P E | -2.8724833 |
| Free Cashflow | -103,812,000 |
| Full Exchange Name | NYSE |
| Full Time Employees | 188 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | -0.32157 |
| Gross Profits | -26,162,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12917 |
| Held Percent Institutions | 0.66486 |
| Implied Shares Outstanding | 127,044,356 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-05-15 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. |
| Long Name | ADC Therapeutics SA |
| Market | us_market |
| Market Cap | 543,749,824 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_183083930 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -142,623,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 543,749,843 |
| Number Of Analyst Opinions | 5 |
| Open | 4.44 |
| Operating Cashflow | -141,174,000 |
| Operating Margins | -0.69317 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 41 21 653 02 00 |
| Post Market Change | -0.03000021 |
| Post Market Change Percent | -0.7009395 |
| Post Market Price | 4.25 |
| Post Market Time | 1,776,464,221 |
| Previous Close | 4.38 |
| Price Hint | 4 |
| Price To Book | -2.8958051 |
| Price To Sales Trailing12 Months | 6.6835036 |
| Profit Margins | -1.75305 |
| Quick Ratio | 4.14 |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | -0.0999999 |
| Regular Market Change Percent | -2.2831 |
| Regular Market Day High | 4.5 |
| Regular Market Day Low | 4.28 |
| Regular Market Day Range | 4.28 - 4.5 |
| Regular Market Open | 4.44 |
| Regular Market Previous Close | 4.38 |
| Regular Market Price | 4.28 |
| Regular Market Time | 1,776,456,002 |
| Regular Market Volume | 544,604 |
| Return On Assets | -0.20557 |
| Revenue Growth | 0.364 |
| Revenue Per Share | 0.64 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 127,044,356 |
| Shares Percent Shares Out | 0.038599998 |
| Shares Short | 4,901,943 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 4,108,452 |
| Short Name | ADC Therapeutics SA |
| Short Percent Of Float | 0.0463 |
| Short Ratio | 5.31 |
| Source Interval | 15 |
| Symbol | ADCT |
| Target High Price | 10.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 8.2 |
| Target Median Price | 8.0 |
| Total Cash | 261,338,000 |
| Total Cash Per Share | 2.057 |
| Total Debt | 439,548,992 |
| Total Revenue | 81,357,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.12 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.7308 |
| Two Hundred Day Average Change | 0.5492003 |
| Two Hundred Day Average Change Percent | 0.14720711 |
| Type Disp | Equity |
| Volume | 544,604 |
| Website | https://www.adctherapeutics.com |
| Zip | 1,066 |